Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.51M | $12.0M | $10.1M | $8.50M | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Revenue growth | — | 26.3% | -15.6% | -16.1% | 111.5% | 54.6% | 29.9% | -14.8% | -7.4% |
| Operating income | -$23.2M | -$20.4M | -$25.9M | -$38.6M | -$77.1M | -$132M | -$215M | -$104M | -$33.3M |
| Operating margin | -244.3% | -170.1% | -255.4% | -453.4% | -428.8% | -473.7% | -596.0% | -337.9% | -116.9% |
| Net income | -$23.4M | -$18.5M | -$29.8M | -$41.1M | -$72.4M | -$133M | -$232M | -$112M | -$26.4M |
| Net margin | -245.8% | -154.1% | -294.3% | -483.4% | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% |
| EPS (diluted) | -$8.65 | -$2.61 | -$1.99 | -$0.39 | -$0.26 | -$4.58 | -$408.60 | -$88.13 | -$4.85 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.8M | -$19.9M | -$29.5M | -$38.3M | -$71.9M | -$125M | -$125M | -$68.9M | -$16.3M |
| Capital expenditures | $1.02M | $332K | $61.1K | $0.00 | — | — | — | — | — |
| Free cash flow | -$21.8M | -$20.3M | -$29.6M | -$38.3M | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.02M | $16.5M | $17.3M | $38.4M | $24.6M | $5.09M | $17.9M | $9.17M | $2.99M |
| Total assets | $10.1M | $24.8M | $30.2M | $60.5M | $377M | $308M | $214M | $76.7M | $73.6M |
| Total liabilities | $17.4M | $14.7M | $26.6M | $25.4M | $40.0M | $58.1M | $118M | $41.3M | $29.2M |
| Long-term debt | $0.00 | $9.03M | $0.00 | $16.3M | $0.00 | — | — | — | — |
| Shareholders' equity | -$50.2M | $10.1M | $3.61M | $35.1M | $337M | $249M | $96.2M | $35.4M | $44.4M |
| Retained earnings | -$54.3M | -$72.8M | -$103M | -$144M | -$216M | -$349M | -$581M | -$693M | -$720M |
| Shares (wtd avg diluted) | 77.3B | 10.1M | 34.3M | 190M | 277M | 28.9M | 569K | 1.27M | 5.45M |
Every figure is extracted from Bionano Genomics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.